Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07337902 · ClinicalTrials.gov registry record · NA
Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)
A NA study of Crohn's Disease (CD) and Dysmenorrhea Primary, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07337902 is a NA study of Crohn's Disease (CD) and Dysmenorrhea Primary that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 24 participants, below the 197-participant average among 5 other Crohn's Disease (CD) trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07337902, a NA study of Crohn's Disease (CD) and Dysmenorrhea Primary, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to prepare for a larger study that will compare the effectiveness and safety of two common pain medications, ibuprofen and acetaminophen, to help treat period cramps in women with Crohn's disease. The goal of this study is to identify any challenges in running a larger study. The investigators will track how many people sign up for the study, how well participants follow the study plan, how many people stay in the study, and whether they are able to complete all the study activities, such as taking the medication, submitting samples, and filling out surveys. During the study, participants will undergo a screening visit that includes a blood draw, physical exam, pregnancy test, stool testing, and complete surveys about Crohn's disease and menstrual cycles. Once this visit is complete, the rest of the study will occur at home. Participants will be assigned to take either ibuprofen or acetaminophen to help treat period cramps for four menstrual cycles in a row. Participants will take ibuprofen for two cycles and acetaminophen for two cycles. Participants will know which medication is being taken at any given time, but the order in which they take the medications will be randomly assigned. Before each menstrual cycle, participants will submit a stool sample and fill out a short (\<1 minute) electronic survey. When participants develop period cramps, they will take the assigned medication for three days and fill out short (\<1 minute) electronic surveys about their cramps. After participants finish taking the medication for three days, they will submit another stool sample and fill out two more short (\<1 minute) electronic surveys. After have completing this process for four menstrual cycles, a remote interview with a researcher to give feedback on the study will be conducted.
Conditions Studied
Interventions
- OTHER Acetaminophen
- OTHER Ibuprofen
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-03-18 |
| Est. Completion | 2028-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07337902
The ClinicalTrials.gov registry entry for NCT07337902 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 5 other Crohn's Disease (CD) trials with a reported enrollment target (88% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Crohn's Disease (CD) appearing as the primary indexed condition, and to 2 interventions - of which Acetaminophen is the first listed.
NCT07337902 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT07337902 about?
NCT07337902 is a clinical study titled "Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)". The purpose of this pilot study is to prepare for a larger study that will compare the effectiveness and safety of two common pain medications, ibuprofen and acetaminophen, to help treat period cramps in women with Crohn's disease. The goal of this study is to identify any challenges in running a la...
What is the current status of trial NCT07337902?
This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2026-03-18. Estimated completion is 2028-07.
What conditions does trial NCT07337902 study?
This clinical trial studies the following conditions: Crohn's Disease (CD), Dysmenorrhea Primary.
What interventions are being tested in trial NCT07337902?
The interventions under investigation include: Acetaminophen (OTHER), Ibuprofen (OTHER).
Who is sponsoring clinical trial NCT07337902?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07337902 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease (CD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D
COMPLETED · NA
-
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RECRUITING
-
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
RECRUITING · Phase 3
-
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.